Pay in 4 interest-free payments of $7.50 Learn more
Ships within 48 hours · Estimated delivery Jul 27 - Aug 1
(2011) Breast Cancer Res
and survival
Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors
ML228 was used at 10 µM final concentration in various in vitro assays
5-a]pyrimidin-3-yl]-2-methyl-
AZD-9291 - CAS# 1421373-65-0 0084 (2011) Breast Cancer ResAZD 9291, CAS No. 1421373 65 0, also known as Osimertinib and Mereletinib, is a third generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors. AZD9291 is highly active in preclinical models and is well tolerated in animal models. It inhibits both activating and resistant EGFR mutations while sparing the normal form of EGFR that is